ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1968

The Specific Role of Vesicle-Associated Membrane Protein-Associated Protein B/C(VapB) As a Regulator of Osteoclastogenesis Via Modulation of Phospholipase Cã(PLCã2-Ca2+-NFAT Signaling

Chang-Hoon Lee1, Wan-Hee Yoo2, Jin-Jung Choi3, Myong-Joo Hong4, Ji-Min Kim5 and Sik-Won Choi6, 1Department of Internal Medicine, School of Medicine, Wonkwang University, Iksan, Chonbuk, South Korea, 2Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, 3Internal Medicine, CHA University Hospital, Seongnam, South Korea, 4Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Daegu, South Korea, 6Department of Anatomy and Institute for Skeletal Disease, School of medicine, Wonkwang university, Iksan, Chonbuk, South Korea

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: osteoclasts and phospholipase, RANK/RANKL pathway

  • Tweet
  • Email
  • Print
Session Information

Title: Osteoporosis and Metabolic Bone Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: Recently,  Vesicle-Associated Membrane Protein-Associated Protein B/C(VapB) has been shown to regulate calcium homeostasis in myotrophic lateral sclerosis. Calcium signalingis also important in metabolic bone diseases, but the role of VapB in the generation of osteoclasts for bone resorption during osteoclastogenesis is not known. Therefore, we investigated the role of VapB in RANKL-induced osteoclast differentiation

Methods: Osteoclast formation was evaluated in bone marrow cells (BMC) in specific  condition with over-expression of VapB or down- regulation of VapB during receptor activator of NF-κB ligand (RANKL)- mediated osteoclastogenesis.. The expression of c-fos and NFATc1 mRNA in osteoclast precursor were assessed by RT-PCR. The levels of c-fos and NFATc1 protein were assessed by western blot. Also the mitogen-activated protein (MAPK)s pathways were measured using Western blot analysis.

Results: We found that VapB is induced during osteoclastogenesis, and regulates osteoclast differentiation by modulating NFATc1. The results suggest that VapB regulates osteoclastogenesis via of Phospholipase Cγ (PLCγ)2-Ca2+-NFAT signaling. The involvement of PLCγ2-Ca2+-NFAT signaling in VapB-regulated osteoclastogenesis was confirmed by a pharmacological study.

Conclusion: Taken together, these results indicate that VapB positively regulates RANKL-mediated osteoclastogenesis via PLCγ2-Ca2+-NFAT signaling and may provide a basis for exploring the therapeutic potential of VapB silencing for metabolic bone diseases, such as osteoporosis and rheumatoid arthritis


Disclosure:

C. H. Lee,
None;

W. H. Yoo,
None;

J. J. Choi,
None;

M. J. Hong,
None;

J. M. Kim,
None;

S. W. Choi,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-specific-role-of-vesicle-associated-membrane-protein-associated-protein-bcvapb-as-a-regulator-of-osteoclastogenesis-via-modulation-of-phospholipase-caplca2-ca2-nfat-signaling/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology